Apply to Trial

Compensation: Varies

Number of Visits: Unknown

Duration: 3 months

AI Speech-to-Text Tool for Heart Failure

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Stanford University

Disqualifiers: Diminished decision-making, Non-English speakers, others

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests an AI Voice Assistant to determine if it can help people with heart failure share health information more easily with their doctors. The researchers aim to find out if this tool can accurately capture patient-reported health information and improve communication with healthcare teams. Participants will use both the AI tool and a paper survey to compare results. Adults with heart failure receiving cardiology care at Stanford University who can clearly communicate in English may be suitable for this study. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance patient-doctor communication.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What prior data suggests that this AI Voice Assistant is safe for capturing patient-reported health information?

Research has shown that AI voice assistants are generally safe to use. Studies have found that these tools can assist in patient care after heart procedures by identifying problems early and enabling safe early discharge from the hospital. One study found that patients using a virtual voice assistant experienced a low rate of complications.

Although specific data on side effects or negative events is lacking, these studies suggest that AI voice assistants are well-tolerated and do not pose major safety concerns. The primary goal is to gather health information to enhance communication with healthcare teams, rather than to administer a drug or medical treatment, which often carries more risk.¹ ² ³ ⁴ ⁵

Why are researchers excited about this trial?

Researchers are excited about the AI Voice Assistant for heart failure because it offers a new, technology-driven approach to patient monitoring and communication. Unlike traditional methods that rely on in-person visits and manual data entry, this AI tool can capture patient-reported outcomes in real-time through natural conversation. This not only makes it easier for patients to share their symptoms and experiences but also allows for quicker data analysis and potentially faster interventions. By integrating AI into patient care, there's hope for more personalized and timely management of heart failure, which could improve overall treatment outcomes.

What evidence suggests that this AI Voice Assistant is effective for heart failure?

Research has shown that AI tools can help manage heart failure. Studies have found that AI can detect early signs of heart failure by analyzing changes in a person's voice. One study showed that AI assistants can improve patient health, reducing hospital visits by 18% for those with congestive heart failure. AI can also analyze heart test data to identify other heart problems. In this trial, participants in the AI Voice Assistant arm will interact with an AI voice assistant tool, which may gather important health information from patients, aiding doctors in making better treatment decisions.¹ ⁴ ⁶ ⁷ ⁸

Who Is on the Research Team?

Alexander Sandhu, MD, MS

Principal Investigator

Stanford University

Are You a Good Fit for This Trial?

This trial is for adults with heart failure who are under cardiology care at Stanford University. Participants must understand and communicate in English well enough to follow study procedures. Those with conditions that could risk their safety or affect the study's outcome, or have diminished decision-making capacity, cannot join.

Inclusion Criteria

Adults with heart failure receiving cardiology care at Stanford University

Exclusion Criteria

Inability to understand and communicate in English sufficiently to complete study procedures

Inability to complete study procedures to the best of the participant's and investigator's knowledge

Any disorder or condition that, in the opinion of the investigator would pose a risk to participant safety or interfere with the study evaluation, procedures or completion

See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants interact with the AI Voice Assistant tool and complete a paper survey

3 months

Follow-up

Participants are monitored for usability, agreement, and accuracy of the AI Voice Assistant

3 months

What Are the Treatments Tested in This Trial?

Interventions

AI Voice Assistant

Trial Overview The trial is testing an AI Voice Assistant as a speech-to-text tool to see if it can accurately collect health information reported by patients themselves, aiming to improve communication between heart failure patients and their healthcare teams.

How Is the Trial Designed?

1Treatment groups

Experimental Treatment

Group I: AI Voice AssistantExperimental Treatment1 Intervention

Participants in the AI Voice Assistant arm will complete two activities: (1) an interaction with the AI Voice Assistant tool and (2) Paper survey that includes the same questions asked by AI voice assistant. Half of the participants will use the AI Voice Assistant first, while the other half will begin with the paper survey.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+

Citations

1.pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov/articles/PMC7617907/

The Emerging Role of Artificial Intelligence in Heart FailureHeart Failure as a field, with its multi-modal data set and variability in outcomes, will greatly benefit from the expansion and improvement of ...

2.clinicaltrials.govclinicaltrials.gov/study/NCT07217366

Speech-to-text Tool for Heart Failure Patient-Reported DataWe will compare agreement the AI Voice Assistant summary to patient-reported responses on the same data elements, including vital signs (heart ...

3.ahajournals.orgahajournals.org/doi/10.1161/CIR.0000000000001201

Use of Artificial Intelligence in Improving Outcomes in Heart ...AI/ML of the ECG can identify other structural heart disease, including hypertrophic cardiomyopathy, amyloid heart disease, aortic stenosis, and ...

4.academic.oup.comacademic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehaf784.4423/8312826

AI-driven voice analysis for early fluid overload detection in ...Our findings suggest that AI-driven voice analysis is a feasible biomarker for detecting heart failure decompensation. While not directly ...

5.nasdaq.comnasdaq.com/articles/counterpart-health-research-highlights-impact-ai-assistant-heart-failure-management

Counterpart Health Research Highlights Impact of AI ...Counterpart Assistant is linked to significant improvements in patient outcomes for congestive heart failure, including an 18% reduction in ...

6.pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov/articles/PMC8214838/

Feasibility of Incorporating Voice Technology and Virtual ...Primary outcome is comfort using voice-assistant technology, and secondary outcomes include heart failure hospitalization and medication adherence at 3 months.

7.pharmaphorum.compharmaphorum.com/news/ai-voice-assistant-can-spot-complications-heart-patients

AI voice assistant can spot complications in heart patientsA virtual voice assistant used to contact patients after heart procedures can make early discharge possible and spot complications.

8.escardio.orgescardio.org/The-ESC/Press-Office/Press-releases/AI-based-virtual-voice-assistant-successfully-bridges-care-gap-for-heart-patients

AI-based virtual voice assistant successfully bridges care ...The TeleTAVI study found that follow-up with a virtual voice assistant enabled safe and early discharge after TAVI, with a low complication rate.

Other People Viewed

By Subject

By Trial